Asthma

Results of ANDHI provide additional support on the safety and efficacy of benralizumab for patients with asthma.

Dupilumab significantly reduces exacerbation rates in patients with asthma compared to standard of care.

In a study presented virtually at ATS 2020, investigators find 15 mg of the study drug resulted in a 43% decrease in FeNO.

A new case study  assesses biopsy and autopsy tissues to characterize pathological patterns in suspected EVALI cases .

In a study presented at ATS 2020, investigators test 3 different dosing regimens of tezepelumab in asthma patients with both high and low levels of IL-5 and IL-13.

A one-time intramuscular dose of the investigative drug was linked to reduced medical attention and hospitalizations related to RSV.

New findings suggest differing chronic lung diseases are associated with varying risk factors among COVID-19 patients.

There is also an association between late onset of spring and an increase in hospital admissions for asthma.

ADHD, autism spectrum disorder, seizures, and even developmental delays are asssociated with a two-fold risk of asthma in US children.

The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.

What risks of severity do patients face with viral infection?

A new Canadian Thoracic Society guidance sets recommendations for continued or halted use of inhaled steroids, nebulizers, biologics, and more.

How clinical data for the interleukin-targeting class will begin to dictate more treatement decisions and research progression.

Asthmatic infants often suffer from other comorbidities throughout their lives.

Blood eosinophil count, exacerbation rate, and time to exacerbation were all bettered among patients who sustained therapy versus those who discontinued.

In an abstract presenting during the ATS conference, investigators find infants with asthma are surprisingly older on the epigentic clock.

New findings from ATS show the residual effects of vaping-associated lung distress.

The lead PATHWAY investigator explains the intent and outcomes from the most recent phase 2B findings.

A discussion with a study author on promising new findings for the combination inhaler therapy.

A new assessment shows risk reduction is even more significant among COPD patients who have smoked.